Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10
Oncocyte Corporation (Nasdaq: OCX) has announced the release of its financial and operating results for the fourth quarter and year ending December 31, 2021, set for March 10, 2022, post U.S. market close. A conference call will follow at 4:30 PM ET to discuss the results and corporate developments. Oncocyte specializes in precision diagnostics for cancer treatment, offering tests like DetermaRx™ and DetermaIO™ that aid in the diagnosis and monitoring of cancer. The company aims to enhance patient outcomes through its innovative diagnostics solutions.
- Oncocyte specializes in precision diagnostics and monitoring for cancer, potentially attracting more investors.
- The upcoming financial results may provide insights into the company's revenue and growth metrics.
- The announcement does not provide any financial metrics or guidance, leaving investors uncertain about performance.
IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it will release its financial and operating results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the close of the U.S. financial markets. The Company will host a conference call on Thursday, March 10, 2022, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.
The dial-in number in the U.S./Canada is 877-407-9716; for international participants, the number is 201-493-6779. For all callers, please refer to Conference ID 13726740. To access the live webcast, go to the investor relations section on the Company’s website, or by clicking here: https://viavid.webcasts.com/starthere.jsp?ei=1526783&tp_key=769c96014b
About Oncocyte
Oncocyte is a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™, a gene expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, blood-based monitoring test DetermaCNI™, and long-term recurrence monitoring test DetermaMx™. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and TheraSure™ are trademarks of Oncocyte Corporation.
Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com
Media Contact
Megan Kernan
ICR Westwicke Healthcare PR
646-677-1870
Megan.Kernan@westwicke.com
Source: Oncocyte Corporation
FAQ
When will Oncocyte release its fourth quarter and full year financial results?
What is Oncocyte's stock symbol?
When is the conference call to discuss Oncocyte's financial results?
What services does Oncocyte provide?
